“We do not inherit the Earth from our ancestors; we borrow it from our children.”

Antoine de Saint-Exupéry

The long-term objective of Tafalgie is to become a European center of excellence in the domain of pain by addressing a medical need that is poorly met, if at all, worldwide, but our commitment extends well beyond that.

Very early on, we decided to embed corporate social responsibility at the heart of our development, with the aim of contributing to the construction of a healthier and more resilient world for patients, the planet and society.

Luc Riols

« We believe that therapeutic innovation and social responsibility must advance together. It is by combining scientific excellence and societal commitment that we will build a durable and influential biotechnology.»

Luc Riols – Président.

The five pillars of the CSR strategy of Tafalgie

With the desire to set an example through our actions and our behavior, we follow a route map based on five priority objectives, with concrete plans of action to be implemented to attain them.

1. Towards better pain management

Supporting innovation to respond more effectively to the needs of patients and to continually increase the efficacy of our treatments whilst rendering them as accessible as possible.

The primary mission of the company is to meet the urgent need to propose an effective treatment for moderate to severe pain in the current context of an opioid crisis and an increasing prevalence of chronic pain.

With its innovative non-opioid products with an excellent safety profile, Tafalgie Therapeutics aims to improve significantly the fate of millions of patients suffering from pain.

However, our ambitions in terms of access to treatment are even greater: we would like our treatments to be distributed on all continents and particularly in developing countries and rural zones.

ZOOM : Focus on pain at work:

30%

des français sont sujets à
DES DOULEURS CHRONIQUES

45%

of whom

seraient concernés par des
ARRÊTS DE TRAVAIL

months

la durée moyenne des
ARRÊTS DE TRAVAIL

Tafalgie collaborates with the reference organizations Pain Alliance Europe & Pain Society, both of which are represented on our clinical advisory board.

2. Establishing durable links with our teams

Tafalgie’s force is its team spirit, which is able to express itself fully in an environment of confidence, respect and integrity. Our talented international and multicultural staff are a determinant advantage for creating the conditions for value creation and sharing. We aim to provide our workers with an inclusive, benevolent and respectful working environment in which diversity is seen as a strength.

We take care to ensure that our collaborators are recruited, welcomed and treated equally, without distinction on the basis of origin, gender, age, religion, sexual orientation or handicap.

Personal/professional life balance

Regular implementation of actions to favor personal and professional development.

Training

Strengthening internal skills and helping each of our collaborators with their own professional development.

remuneration

As a means of strengthening the motivation and fidelity of our talent, remuneration packages include a variable portion linked to the attainment of clear objectives and a long-term profit-sharing scheme.

3. Environmental commitment

Conscious of the climatic and environmental emergency in which we find ourselves, we have initiated a structured approach aiming to minimize our impact on the planet.

The carbon footprint of our entire value chain (frames 1, 2 and 3) has been evaluated in collaboration with a specialist company. This approach has enabled us to identify our principal emissions and to establish a plan for decreasing them.

Everyday actions:

Sorting of waste,

Sobriety in energy use,

Regular actions to raise the awareness of our teams

4. Quality assurance and business ethics

In the biotechnology sector, quality assurance and business ethics are absolutely primordial for guaranteeing the conformity, safety and efficacy of products. This responsible conduct led Tafalgie to establish a quality assurance policy that places our stakeholders (patients, healthcare professionals, regulatory authorities, clients, partners, etc.) at the heart of our priorities and enables us to target operational excellence such that we can propose high-quality drugs conforming to regulatory requirements and meeting the needs of patients.

Other actions implemented:

Protection of personal data (in accordance with the GDPR)

Communication and transparency between the company and its shareholders
(quarterly communications and twice-yearly shareholders’ meetings).

5. Long-term integration into the local environment

As an IBDM CNRS/Aix-Marseille University spinoff, Tafalgie has been rooted in the local environment of the Marseille area since its creation, and its history is closely linked to this town and its region.

The company aims to conserve and develop fruitful collaborations with the local and European ecosystem, creating an internationally recognized research and development center in the domain of pain in Marseille.